Cooley LLP announced today that it advised Versartis, Inc. on its $144.9 million initial public offering. Versartis, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders, now trades on the NASDAQ Global Stock Market under the symbol “VSAR.”
The Cooley corporate and securities team advising Versartis included partner and head of the life sciences practice Barbara Kosacz, partners Kenn Guernsey and Mike Tenta, and associates Siana Lowrey, Amanda Busch and Alexis Weiss. Critical support for the offering was provided by partner Renee Deming and associate Sarah Dale (compensation & benefits); partner Natasha Leskovsek (regulatory); partner Michael Tuscan and associate Fraser Brown (patent counseling & prosecution); and associate Bin Wang (life sciences).
Year-to-date in 2014, Cooley has advised on 38 completed public offerings, including 17 completed IPOs.
Related Posts:
- Cooley Advises Underwriters on Five Prime Therapeutics IPO
- Cooley Advises Underwriters on Zendesk’s $115 Million Initial Public Offering
- Cooley Advises TriNet on its $276 Million Initial Public Offering
- Dermira Prices its Initial Public Offering
- Cooley Advises Underwriters in Proto Labs IPO
